CTOS 2021

Long-Term Safety Data Support Benefit-Risk Profile of NBTXR3 Plus Radiotherapy in Locally Advanced Soft Tissue Sarcoma

By

Andrea S. Blevins Primeau, PhD, MBA

NBTXR3 plus radiotherapy did not negatively affect quality of life or long-term morbidity in locally advanced soft tissue sarcoma.

Lack of Radiosensitivity Associated With Poor Outcomes in Myxoid Liposarcomas

By

Andrea S. Blevins Primeau, PhD, MBA

Researchers found that lack of radiosensitivity was associated with poor outcomes in patients with myxoid liposarcomas.

Radiotherapy May Improve Outcomes in Extremity Soft Tissue Sarcoma

By

Andrea S. Blevins Primeau, PhD, MBA

Neoadjuvant and adjuvant radiotherapy were associated with a reduced risk of local recurrence.

Immune Checkpoint Inhibitors May Offer Benefit in Recurrent Chordoma

By

Andrea S. Blevins Primeau, PhD, MBA

Most patients included in the retrospective analysis received ICI treatment as their first line of therapy (59%).

Regimen May Be Beneficial as Palliative Care for Children, Young Adults With Solid Tumors

By

Andrea S. Blevins Primeau, PhD, MBA

Stable disease was observed in 51.3% of patients.

Lower Household Income May Increase Risk of Amputation in Extremity Bone Sarcoma

By

Andrea S. Blevins Primeau, PhD, MBA

Amputation was significantly more likely in patients with household incomes below $75,000 per year.

High Rate of Complications Reported in Sarcoma Patients With COVID-19

By

Andrea S. Blevins Primeau, PhD, MBA

The hospitalization rate was 49%, and 16% of patients died.

Survival Benefit Persists With Fourth-Line Ripretinib in GIST

By

Andrea S. Blevins Primeau, PhD, MBA

The 24-month overall survival rate was 42.8%.